Structure-guided design of a selective BCL-XL inhibitor

Nature Chemical Biology

Volumn 9, Issue 6, 2013, Pages 390-397

  Lessene, Guillaume ^a,b   Czabotar, Peter E ^a,b,e   Sleebs, Brad E ^a,b,e   Zobel, Kerry ^c   Lowes, Kym N ^a,b   Adams, Jerry M ^a,b   Baell, Jonathan B ^a,b,d   Colman, Peter M ^a,b   Deshayes, Kurt ^c   Fairbrother, Wayne J ^c   Flygare, John A ^c   Gibbons, Paul ^c   Kersten, Wilhelmus J A ^a,b   Kulasegaram, Sanji ^a,b,e   Moss, Rebecca M ^a,b   Parisot, John P ^a,b,f   Smith, Brian J ^a,b,g   Street, Ian P ^a,b   Yang, Hong ^a,b   Huang, David C S ^a,b   Watson, Keith G ^a,b   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c GENENTECH INC   (United States)

^d MONASH UNIVERSITY   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL XL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WEHI 539;

ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BENZOTHIAZOLES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDRAZONES; KINETICS; MICE; MODELS, CHEMICAL; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84879126792     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1246     Document Type: Article

References (56)

1. Hotchkiss, R.S., Strasser, A., McDunn, J.E. & Swanson, P.E. Cell death. N. Engl. J. Med. 361, 1570-1583 (2009).
2. Strasser, A., Cory, S. & Adams, J.M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 30, 3667-3683 (2011).
3. Glaser, S.P. et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26, 120-125 (2012).
4. Lessene, G., Czabotar, P.E. & Colman, P.M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7, 989-1000 (2008).
5. Wells, J.A. & McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007).
6. Mullard, A. Protein-protein interaction inhibitors get into the groove. Nat. Rev. Drug Discov. 11, 173-175 (2012).
7. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
8. Amundson, S.A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101-6110 (2000).
9. Vaux, D.L., Cory, S. & Adams, J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335, 440-442 (1988).
10. Strasser, A., Harris, A.W., Bath, M.L. & Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331-333 (1990).
11. Kelly, P.N. & Strasser, A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18, 1414-1424 (2011).
12. Lindsten, T. et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 6, 1389-1399 (2000).
13. Leber, B., Lin, J. & Andrews, D.W. Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene 29, 5221-5230 (2010).
14. Leber, B., Lin, J. & Andrews, D.W. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 12, 897-911 (2007).
15. Labi, V., Grespi, F., Baumgartner, F. & Villunger, A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ. 15, 977-987 (2008).
16. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
17. Rudin, C.M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163-3169 (2012).
18. Gandhi, L. et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916 (2011).
19. Roberts, A.W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488-496 (2012).
20. Wilson, W.H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149-1159 (2010).
21. Park, C.M. et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J. Med. Chem. 51, 6902-6915 (2008).
22. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
23. Souers, A.J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013).
24. Mason, K.D. et al. Programmed anuclear cell death delimits platelet life span. Cell 128, 1173-1186 (2007).
25. Zhang, H. et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14, 943-951 (2007).
26. Baell, J.B. & Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010).
27. L/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci. 9, 2528-2534 (2000).
28. Petros, A.M., Olejniczak, E.T. & Fesik, S.W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83-94 (2004).
29. L: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 14, 1711-1713 (2007).
30. L/Bim fragment complex: implications for Bim function. Immunity 19, 341-352 (2003).
31. L-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. J. Biol. Chem. 282, 13123-13132 (2007).
32. L-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983-986 (1997).
33. Lee, E.F. et al. Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands. J. Biol. Chem. 284, 30508-30517 (2009).
34. Wendt, M.D. et al. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J. Med. Chem. 49, 1165-1181 (2006).
35. Chen, L. et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403 (2005).
36. Czabotar, P.E. & Lessene, G. Bcl-2 family proteins as therapeutic targets. Curr. Pharm. Des. 16, 3132-3148 (2010).
37. van Delft, M.F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399 (2006).
38. van Delft, M.F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399 (2006).
39. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19, 1294-1305 (2005).
40. Lee, E.F. et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J. Cell Biol. 180, 341-355 (2008).
41. L, and Bcl-W are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 119, 5807-5816 (2012).
42. Josefsson, E.C. et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J. Exp. Med. 208, 2017-2031 (2011).
43. Gleeson, M.P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 51, 817-834 (2008).
44. L potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 66, 8731-8739 (2006).
45. Czabotar, P.E. et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc. Natl. Acad. Sci. USA 104, 6217-6222 (2007).
46. Willis, S.N. et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856-859 (2007).
47. Fletcher, J.I. et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc. Natl. Acad. Sci. USA 105, 18081-18087 (2008).
48. Smits, C., Czabotar, P.E., Hinds, M.G. & Day, C.L. Structural plasticity underpins promiscuous binding of the prosurvival protein A1. Structure 16, 818-829 (2008).
49. L, an inhibitor of programmed cell death. Nature 381, 335-341 (1996).
50. Kvansakul, M. et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ. 15, 1564-1571 (2008).
51. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276, 307-326 (1997).
52. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D Biol. Crystallogr. 66, 133-144 (2010).
53. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
54. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
55. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
56. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).